Rigel Pharmaceuticals's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross.

Rigel Pharmaceuticals' 15-minute chart has exhibited Bollinger Bands Narrowing and a KDJ Death Cross at 08/18/2025 15:00. This suggests a decline in the magnitude of stock price fluctuations and a shift in momentum towards a downward trend, with the potential for further decreases in stock price.

Rigel Pharmaceuticals (NASDAQ: RIGL) reported robust Q2 earnings, driving a potential breakout above $30 per share. The company's total revenue surged to $101.7 million, nearly doubling year-over-year, with $58.9 million in net product sales, a 76% year-over-year increase [1]. Rigel's flagship product, TAVALISSE, contributed $40.1 million, up 52% year-over-year, while GAVRETO and REZLIDHIA also showed strong sales growth. The company's net income jumped to $59.6 million, compared to a $1 million net loss a year ago. Rigel also raised its full-year revenue guidance to $270 million–$280 million, expecting net product sales to reach $210 million–$220 million [1].

Rigel's pipeline progress is another positive indicator. The company's lead internal program, R289, is in Phase Ib for lower-risk myelodysplastic syndromes (MDS), with enrollment for the dose escalation portion finished and data updates expected later this year. REZLIDHIA (olutasidenib) is also expanding its use into neuro-oncology, with a Phase II trial assessing olutasidenib with temozolomide in young patients with IDH1-mutant high-grade glioma [1].

However, several risks must be considered. The non-cash nature of the $40 million Lilly revenue strengthened the income statement but won't recur. The company's commercial performance might face a step back in Q3 and Q4, and clinical execution risks are always present in late-stage trials. Rigel's competition could also limit its growth. Despite these risks, Rigel's performance and pipeline potential make it a compelling investment, especially with its recent price appreciation [1].

References:
[1] https://seekingalpha.com/article/4813426-rigel-pharmaceuticals-q2-earnings-fuel-potential-breakout